Age Related Macular Degeneration Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Age Related Macular Degeneration Pipeline Drugs Market Overview
Age related macular degeneration is the most common reason for vision loss in people aged above 50. It results in the depreciation of the macula which may lead to distorted or blurry central vision. The predisposing factors involved are age, smoking, sunlight, heredity, etc. Symptoms include the development of blind spots and hazy vision. The condition may be treated by photodynamic therapy, radiation therapy, and medication such as anti-angiogenic drugs.
The Age Related Macular Degeneration pipeline drugs market research report provides comprehensive information on the therapeutics under development for Age Related Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Age Related Macular Degeneration and features dormant and discontinued projects.
Key Targets | Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor, Angiopoietin 2, Angiopoietin 1 Receptor, and Others |
Key Mechanisms of Action | Vascular Endothelial Growth Factor A Inhibitor, Vascular Endothelial Growth Factor Inhibitor, Angiopoietin 2 Inhibitor, Placenta Growth Factor Inhibitor, Angiopoietin 1 Receptor Agonist, and Others |
Key Routes of Administration | Intravitreal, Oral, Ophthalmic, Intraocular, and Others |
Key Molecule Type | Small Molecule, Monoclonal Antibody, Gene Therapy, Biologic, and Others |
Leading Companies | Nextgen Bioscience, Shanghai Novamab Biopharmaceuticals Co Ltd, YD Life Science Co, AmMax Bio Inc, and Others |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Age Related Macular Degeneration Pipeline Drugs Market Segmentation by Targets
The key targets in the Age Related Macular Degeneration pipeline drugs market are Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor, Angiopoietin 2, Angiopoietin 1 Receptor, and Others. Vascular Endothelial Growth Factor A had the highest number of products in development in the Age Related Macular Degeneration pipeline drugs market, in 2022.
Age Related Macular Degeneration Pipeline Drugs Market Analysis by Targets, 2022 (%)
For more target insights into the Age Related Macular Degeneration pipeline drugs market, download a free report sample
Age Related Macular Degeneration Pipeline Drugs Market Segmentation by Mechanisms of Action
The key mechanisms of action in the Age Related Macular Degeneration pipeline drugs market are Vascular Endothelial Growth Factor A Inhibitor, Vascular Endothelial Growth Factor Inhibitor, Angiopoietin 2 Inhibitor, Placenta Growth Factor Inhibitor, Angiopoietin 1 Receptor Agonist, and Others. Vascular Endothelial Growth Factor A Inhibitor led the Age Related Macular Degeneration pipeline drugs market in terms of MoA in 2022.
Age Related Macular Degeneration Pipeline Drugs Market Analysis by Mechanisms of Action, 2022 (%)
For more MoA insights into the Age Related Macular Degeneration pipeline drugs market, download a free report sample
Age Related Macular Degeneration Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Age Related Macular Degeneration pipeline drugs market intravitreal, oral, ophthalmic, intraocular, and others. The intravitreal RoA had the highest number of Age Related Macular Degeneration drugs in development in 2022.
Age Related Macular Degeneration Pipeline Drugs Market Analysis by Routes of Administration, 2022 (%)
For more MoA insights into the Age Related Macular Degeneration pipeline drugs market, download a free report sample
Age Related Macular Degeneration Pipeline Drugs Market Segmentation by Molecule Types
The key molecule types in the Age Related Macular Degeneration pipeline drugs market are small molecule, monoclonal antibody, gene therapy, biologic, and others. Small molecule led the Age Related Macular Degeneration pipeline drugs market in terms of molecule type in 2022.
Age Related Macular Degeneration Pipeline Drugs Market Analysis by Molecule Types, 2022 (%)
For more molecule type insights into the Age Related Macular Degeneration drugs market, download a free report sample
Age Related Macular Degeneration Pipeline Drugs Market - Competitive Landscape
Some of the leading companies in the Age Related Macular Degeneration pipeline drugs market are Nextgen Bioscience, Shanghai Novamab Biopharmaceuticals Co Ltd, YD Life Science Co, AmMax Bio Inc, and others. Nextgen Bioscience is one of the companies with the highest number of Age Related Macular Degeneration drugs in development in 2022.
Age Related Macular Degeneration Pipeline Drugs Market Analysis by Companies, 2022 (%)
To know more about the leading Age Related Macular Degeneration pipeline drugs market players, download a free report sample
Key Segments Covered in this Report
Age Related Macular Degeneration Pipeline Drugs Target Outlook (No of Drugs, 2022)
- Vascular Endothelial Growth Factor A
- Vascular Endothelial Growth Factor
- Angiopoietin 2
- Angiopoietin 1 Receptor
- Others
Age Related Macular Degeneration Pipeline Drugs MoA Outlook (No of Drugs, 2022)
- Vascular Endothelial Growth Factor A Inhibitor
- Vascular Endothelial Growth Factor Inhibitor
- Angiopoietin 2 Inhibitor
- Placenta Growth Factor Inhibitor
- Angiopoietin 1 Receptor Agonist
- Others
Age Related Macular Degeneration Pipeline Drugs RoA Outlook (No of Drugs, 2022)
- Intravitreal
- Oral
- Ophthalmic
- Intraocular
- Others
Age Related Macular Degeneration Pipeline Drugs Molecule Type Outlook (No of Drugs, 2022)
- Small Molecule
- Monoclonal Antibody
- Gene Therapy
- Biologic
- Others
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Age Related Macular Degeneration.
- The pipeline guide reviews pipeline therapeutics for Age Related Macular Degeneration by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Age Related Macular Degeneration therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Age Related Macular Degeneration therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Age Related Macular Degeneration
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Age Related Macular Degeneration.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the Age Related Macular Degeneration pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
Abfero Pharmaceuticals Inc
Abzyme Therapeutics LLC
Acahealth Pharma and Biotech Co Ltd
Aerie Pharmaceuticals Inc
Alexion Pharmaceuticals Inc
Alkeus Pharmaceuticals Inc
Amarna Therapeutics BV
AMD Therapeutics LLC
AmMax Bio Inc
Amyndas Pharmaceuticals LLC
Amytrx Therapeutics Inc
AngioGenex Inc
Anida Pharma Inc
Applied Genetic Technologies Corp
Aptamer Sciences Inc
Ascentage Pharma Group International
Autophagy Science Co Ltd
Avirmax Inc
Baltymas UAB
Beijing StarMab BioMed Technology Ltd
BellBrook Labs LLC
BenoBio Co Ltd
Biokine Therapeutics Ltd
Biomics Biotechnologies Co Ltd
BioXpress Therapeutics SA
Bonac Corp
BrainEver SAS
Breye Therapeutics ApS
Bridge Biotherapeutics Inc
Broadwing Bio
Carmine Therapeutics Inc
CDR-Life Inc
Celon Pharma SA
Celros Biotech Co Ltd
Character Biosciences Co
Charlesson LLC
Chong Kun Dang Pharmaceutical Corporation
Clayton Biotechnologies Inc
Complement Therapeutics Ltd
ConeSight Therapeutics
Curative Biotechnology Inc
CureLab Oncology Inc
Daiichi Sankyo Co Ltd
EirGenix Inc
Epygen Biotech Pvt Ltd
Excitant Therapeutics LLC
Exegenesis Bio Inc
Eye Bio Korea Co Ltd
F. Hoffmann-La Roche Ltd
Feramda Ltd
Galimedix Therapeutics Ltd
Generoath Co Ltd
Glaceum Inc
Great Bay Bio Holdings Ltd
Hanlim Pharm Co Ltd
ICM Co Ltd
Iconic Therapeutics Inc
Immupharma Plc
Inflammasome Therapeutics Inc
Inflammx Therapeutics Inc
Jecho Biopharmaceuticals Co Ltd
Jenivision Inc
JW Pharmaceutical Corp
Kala Pharmaceuticals Inc
Kiora Pharmaceuticals Inc
Lead Discovery Center GmbH
Lineage Cell Therapeutics Inc
Lysoclear Inc
Mabion SA
maintect GmbH
MD Healthcare Inc
MDimune Inc
Mediolanum farmaceutici SpA
MetiMedi Pharmaceuticals Co Ltd
MitoImmune Therapeutics Inc
Mitsubishi Tanabe Pharma Corp
Mor Research Applications Ltd
Nextgen Bioscience
NGM Biopharmaceuticals Inc
Novartis AG
Noveome Biotherapeutics Inc
OliPass Corporation
Omeros Corp
Oncosimis Biotech Pvt Ltd
Opsis Therapeutics LLC
Paras Biopharmaceuticals Finland Oy
Perceive Biotherapeutics Inc
Phanes Therapeutics Inc
PharmAbcine Inc
Phio Pharmaceuticals Corp
Phision Therapeutics
PlantForm Corp
Pleryon Therapeutics Ltd
Regeneron Pharmaceuticals Inc
Retrotope Inc
RheinCell Therapeutics GmbH
Rophibio Inc
Rudacure Co Ltd
SeaBeLife Spas
Semathera Inc
Shanghai Novamab Biopharmaceuticals Co Ltd
SIFI SpA
SmartinBio
Splash Pharmaceuticals Inc
Sustained Nano Systems LLC
Suzhou Ribo Life Sciences Co Ltd
Suzhou Stainwei Biotech Inc
Sylentis SAU
TALLC Inc
TechnoPhage SA
Tianchen Biopharmaceutical (Suzhou) Co Ltd
TreeFrog Therapeutics SAS
Trican Biotechnology Co Ltd
Uni-Bio Science Group Ltd
Unity Biotechnology Inc
Valitor Inc
ViGeneron GmbH
Visgenx Inc
Wellstat Ophthalmics Corp
YD Life Science Co
Zhejiang Doer Biologics Corp
Zhuhai Qiwei Biotechnology Co Ltd
Zydus Lifesciences Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Age Related Macular Degeneration pipeline drugs market?
The key targets in the Age Related Macular Degeneration pipeline drugs market are Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor, Angiopoietin 2, Angiopoietin 1 Receptor, and others.
-
What are the key mechanisms of action in the Age Related Macular Degeneration pipeline drugs market?
The key MoA in the Age Related Macular Degeneration pipeline drugs market are Vascular Endothelial Growth Factor A Inhibitor, Vascular Endothelial Growth Factor Inhibitor, Angiopoietin 2 Inhibitor, Placenta Growth Factor Inhibitor, Angiopoietin 1 Receptor Agonist, and others.
-
What are the key routes of administration in the Age Related Macular Degeneration pipeline drugs market?
The key RoA in the Age Related Macular Degeneration pipeline drugs market are intravitreal, oral, ophthalmic, intraocular, and others.
-
What are the key molecule types in the Age Related Macular Degeneration pipeline drugs market?
The key molecule types in the Age Related Macular Degeneration pipeline drugs market are small molecule, monoclonal antibody, gene therapy, biologic, and others.
-
Which are the leading companies in the Age Related Macular Degeneration pipeline drugs market?
Some of the leading companies in the Age Related Macular Degeneration pipeline drugs market are Nextgen Bioscience, Shanghai Novamab Biopharmaceuticals Co Ltd, YD Life Science Co, AmMax Bio Inc, and Others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.